[go: up one dir, main page]

HRP20120002T1 - Liječenje mastitisa - Google Patents

Liječenje mastitisa Download PDF

Info

Publication number
HRP20120002T1
HRP20120002T1 HR20120002T HRP20120002T HRP20120002T1 HR P20120002 T1 HRP20120002 T1 HR P20120002T1 HR 20120002 T HR20120002 T HR 20120002T HR P20120002 T HRP20120002 T HR P20120002T HR P20120002 T1 HRP20120002 T1 HR P20120002T1
Authority
HR
Croatia
Prior art keywords
mastitis
indicated
use according
treatment
enrofloxacin
Prior art date
Application number
HR20120002T
Other languages
English (en)
Inventor
Pirro Franz
Fraatz Kristine
Froyman Robrecht
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120002(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of HRP20120002T1 publication Critical patent/HRP20120002T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Uporaba enrofloksacina naznačena time da je za proizvodnju lijeka za paranteralno liječenje mastitisa kod krava pomoću najviše dva intravenozna davanja. Patent sadrži još 3 patentna zahtjeva.

Claims (4)

1. Uporaba enrofloksacina naznačena time da je za proizvodnju lijeka za paranteralno liječenje mastitisa kod krava pomoću najviše dva intravenozna davanja.
2. Uporaba prema zahtjevu 1, naznačena time da se davanje provodi u dva uzastopna dana.
3. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da se davanja provode u svakom slučaju jednom dnevno.
4. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da se dnevno daje 1 mg/kg do 10 mg/kg enrofloksacina.
HR20120002T 2004-11-12 2011-12-30 Liječenje mastitisa HRP20120002T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004054873A DE102004054873A1 (de) 2004-11-12 2004-11-12 Behandlung von Mastitis
PCT/EP2005/011553 WO2006050826A2 (de) 2004-11-12 2005-10-28 Behandlung von mastitis mit enrofloxacin

Publications (1)

Publication Number Publication Date
HRP20120002T1 true HRP20120002T1 (hr) 2012-02-29

Family

ID=35462240

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120002T HRP20120002T1 (hr) 2004-11-12 2011-12-30 Liječenje mastitisa

Country Status (27)

Country Link
US (2) US20070265275A1 (hr)
EP (1) EP1812002B1 (hr)
JP (2) JP2008519781A (hr)
KR (1) KR20070084182A (hr)
CN (1) CN101056638A (hr)
AR (1) AR051763A1 (hr)
AT (1) ATE526970T1 (hr)
BR (1) BRPI0517473A (hr)
CA (1) CA2587187A1 (hr)
CR (1) CR9109A (hr)
DE (2) DE102004054873A1 (hr)
DK (1) DK1812002T3 (hr)
ES (1) ES2373449T3 (hr)
HR (1) HRP20120002T1 (hr)
IL (1) IL182993A (hr)
MX (1) MX2007005526A (hr)
NO (1) NO20072890L (hr)
NZ (1) NZ555062A (hr)
PE (1) PE20061139A1 (hr)
PL (1) PL1812002T3 (hr)
PT (1) PT1812002E (hr)
RU (1) RU2413514C2 (hr)
SI (1) SI1812002T1 (hr)
SV (1) SV2006002296A (hr)
UA (1) UA92593C2 (hr)
WO (1) WO2006050826A2 (hr)
ZA (1) ZA200703695B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5217276B2 (ja) * 2007-07-19 2013-06-19 ニプロ株式会社 注射用抗菌剤の製造方法
GB2480276A (en) * 2010-05-11 2011-11-16 Michael Hilary Burke Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation
CN101933927A (zh) * 2010-06-30 2011-01-05 洛阳惠中兽药有限公司 一种含恩诺沙星六水合物组合物及其在制备治疗或预防家畜疾病的药物中的应用
MX368153B (es) * 2012-06-29 2019-09-20 Bayer Animal Health Gmbh Composiciones farmacéuticas y tratamiento de mastitis.
WO2014150338A1 (en) * 2013-03-15 2014-09-25 Genzyme Corporation Amine functional polyamides
RU2655772C1 (ru) * 2016-12-26 2018-05-29 Федеральное государственное бюджетное научное учреждение "Курский научно-исследовательский институт агропромышленного производства" Йодсодержащий состав для лечения мастита у коров
RU2652354C1 (ru) * 2017-11-07 2018-04-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный аграрный университет" (ФГБОУ ВО Волгоградский ГАУ) Способ терапии коров, больных маститом
CN108051512A (zh) * 2017-11-27 2018-05-18 佛山科学技术学院 一种牛乳中氟喹诺酮类药物残留量的检测方法
CN110812326B (zh) * 2019-11-04 2022-04-22 黑龙江省农业科学院畜牧兽医分院 一种辛伐他汀混悬乳剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3333719A1 (de) 1983-09-17 1985-04-04 Bayer Ag Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
DE3713672A1 (de) 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
DE19500784A1 (de) 1995-01-13 1996-07-18 Bayer Ag Enrofloxacin-Injektions- oder Infusionslösungen
CA2176298C (en) 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment

Also Published As

Publication number Publication date
NZ555062A (en) 2009-12-24
CA2587187A1 (en) 2006-05-18
PL1812002T3 (pl) 2012-03-30
ES2373449T3 (es) 2012-02-03
IL182993A0 (en) 2007-09-20
US20130023540A1 (en) 2013-01-24
IL182993A (en) 2013-03-24
DE202005022066U1 (de) 2012-12-06
DE102004054873A1 (de) 2006-05-18
MX2007005526A (es) 2007-07-09
RU2413514C2 (ru) 2011-03-10
DK1812002T3 (da) 2012-02-06
BRPI0517473A (pt) 2008-10-07
AR051763A1 (es) 2007-02-07
UA92593C2 (ru) 2010-11-25
EP1812002A2 (de) 2007-08-01
WO2006050826A2 (de) 2006-05-18
SV2006002296A (es) 2006-06-26
US20070265275A1 (en) 2007-11-15
EP1812002B1 (de) 2011-10-05
PT1812002E (pt) 2011-12-30
NO20072890L (no) 2007-06-06
SI1812002T1 (sl) 2012-03-30
JP2013063985A (ja) 2013-04-11
CR9109A (es) 2007-10-04
ZA200703695B (en) 2008-08-27
KR20070084182A (ko) 2007-08-24
PE20061139A1 (es) 2006-12-29
JP2008519781A (ja) 2008-06-12
CN101056638A (zh) 2007-10-17
WO2006050826A3 (de) 2006-07-27
RU2007121516A (ru) 2008-12-20
ATE526970T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
HRP20120002T1 (hr) Liječenje mastitisa
RS51688B (en) METHOTREXATE CONCENTRATED SOLUTIONS
RS52831B (en) THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY
IL197393A (en) History of pyridine-4-ram, containing and using pharmaceutical preparations for the preparation of drugs for the treatment of immune-related diseases
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
ES2175415T3 (es) Inhibidores de metaloproteasas matriciales basados en fosfinato.
HRP20150889T1 (hr) Postupci za lijeäśenje adhezivnog kapsulitisa
NO20042364L (no) Formulering av aminosyrer og riboflavin nyttig for a redusere toksiske effekter av cytotoksisk kjemoterapi
ATE464883T1 (de) Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
FI3071563T3 (fi) Syövän vastaisia aineita ja niiden valmistus
WO2012035561A3 (en) Improved oral targetted drug delivery system
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
ATE551999T1 (de) P-glycoprotein-hemmer mit octiloniumbromid als wirkstoff
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
RU2007122391A (ru) S-миртазапин для лечения приливов
WO2021101258A3 (ko) 압타머 기반 표적화 복합 항암제
MXPA06000760A (es) Composicion farmaceutica estable de carisoprodol y meloxicam.
JP2006503049A5 (hr)
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением